Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408272 | 0.96 | MAOB (0.44) | MAOBUSP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL31732340 | 0.94 | MAOB (0.43) | MAOBUSP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL2338409 | 0.91 | USP2 (0.46) | MAOBUSP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL31731796 | 0.90 | HPGD (0.42) | MAOBUSP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL23121120 | 0.87 | USP2 (0.43) | MAOBUSP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL20873847 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL11351472 | 0.85 | MAPT (0.44) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL8253901 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL29617106 | 0.83 | EPHX2 (0.42) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL16899910 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2TLR8CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2022159650-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| CN-110753693-A | EGFR proteolytic targeting chimeric molecules and related methods of use | 阿尔维纳斯运营股份有限公司 | 2020-02-04 | — | — | CN | disclosed |
| EP-3559002-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017013593-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2017-01-26 | — | — | WO | disclosed |
| EP-0839805-B1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | SCHERING AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-5969138-A | ANTIPSYCHOTIC AGENTS | MITSUI CHEMICALS, INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0839805-A1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | MAOB 3590/4885USP2 45/4885SMN1; SMN2 4046/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | MAOB 2915/4885USP2 70/4885SMN1; SMN2 2772/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | MAOB 2915/4885USP2 70/4885SMN1; SMN2 2772/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | MAOB 3590/4885USP2 45/4885SMN1; SMN2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.